Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yivoximab in Metastatic Clear Cell Renal Cell Carcinoma
NCT07488572Phase 2Enrolling by invitation
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of yivoximab in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University. Started Nov 2025; status: enrolling by invitation.
02
Drugs
yivoximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07488572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488572.